KTTA (Pasithea Therapeutics Corp.) Earnings per share for the last four quarters

The stability of Pasithea Therapeutics (KTTA) is based on small molecule patents and grants that protect FCF. Revenue balance is maintained through a combination of ketamine therapy and the development of neurofibromatosis treatments. Production capacities operate strictly according to clinical plans within sterile booths. The current YoY TTM EPS growth rate demonstrates resilience to shocks, with the value 72.60 representing the current metric.
Financial and market metric breakdowns for Pasithea Therapeutics Corp. (KTTA)

This indicator measures the annual growth rate of earnings per share over the last twelve months. By analyzing the EPS YoY TTM trend, an investor assesses profit generation efficiency relative to previous periods. Growth in this metric confirms market resilience, while a decline signals multiple compression. For Pasithea Therapeutics (KTTA), such fluctuations are driven by complexities in reagent procurement. Geopolitical instability is slowing clinical trials, directly limiting the potential for earnings growth.